| __timestamp | ADMA Biologics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 4050200000 |
| Thursday, January 1, 2015 | 4311461 | 5047100000 |
| Friday, January 1, 2016 | 6360761 | 6078400000 |
| Sunday, January 1, 2017 | 29164321 | 6931500000 |
| Monday, January 1, 2018 | 42194635 | 6861900000 |
| Tuesday, January 1, 2019 | 39504238 | 7056300000 |
| Wednesday, January 1, 2020 | 61291426 | 8149300000 |
| Friday, January 1, 2021 | 79769341 | 12310800000 |
| Saturday, January 1, 2022 | 118814535 | 9765700000 |
| Sunday, January 1, 2023 | 169273000 | 8988300000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the biopharmaceutical industry, understanding cost efficiency is crucial. This analysis delves into the cost of revenue trends for Viatris Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently demonstrated a robust cost management strategy, with its cost of revenue peaking in 2021 at approximately $12.3 billion. In contrast, ADMA Biologics, Inc. showed a significant upward trend, with a staggering 4,400% increase from 2014 to 2023, reaching around $169 million. This stark contrast highlights Viatris Inc.'s ability to maintain a stable cost structure, while ADMA Biologics, Inc. is in a phase of rapid growth and expansion. Such insights are invaluable for investors and stakeholders aiming to make informed decisions in this competitive sector.
Analyzing Cost of Revenue: Novo Nordisk A/S and ADMA Biologics, Inc.
Cost Insights: Breaking Down Zoetis Inc. and Viatris Inc.'s Expenses
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and ADMA Biologics, Inc.
Cost of Revenue: Key Insights for Viatris Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Geron Corporation
Cost of Revenue Trends: Viatris Inc. vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and MorphoSys AG's Expenses
Cost of Revenue Comparison: ADMA Biologics, Inc. vs PTC Therapeutics, Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: ADMA Biologics, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and Xencor, Inc.'s Expenses